MDAI vs. LNSR, ZJYL, SRTS, ECOR, TELA, MLSS, FONR, GUTS, MGRM, and NTRB
Should you be buying Spectral AI stock or one of its competitors? The main competitors of Spectral AI include LENSAR (LNSR), Jin Medical International (ZJYL), Sensus Healthcare (SRTS), electroCore (ECOR), TELA Bio (TELA), Milestone Scientific (MLSS), FONAR (FONR), Fractyl Health (GUTS), Monogram Orthopaedics (MGRM), and Nutriband (NTRB). These companies are all part of the "medical equipment" industry.
Spectral AI vs.
LENSAR (NASDAQ:LNSR) and Spectral AI (NASDAQ:MDAI) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, analyst recommendations, media sentiment, risk, earnings, valuation, institutional ownership, community ranking and dividends.
LENSAR has higher revenue and earnings than Spectral AI. LENSAR is trading at a lower price-to-earnings ratio than Spectral AI, indicating that it is currently the more affordable of the two stocks.
LENSAR has a beta of 0.63, indicating that its share price is 37% less volatile than the S&P 500. Comparatively, Spectral AI has a beta of 0.47, indicating that its share price is 53% less volatile than the S&P 500.
LENSAR currently has a consensus price target of $8.00, indicating a potential downside of 26.13%. Spectral AI has a consensus price target of $4.75, indicating a potential upside of 159.56%. Given Spectral AI's stronger consensus rating and higher probable upside, analysts clearly believe Spectral AI is more favorable than LENSAR.
In the previous week, Spectral AI had 2 more articles in the media than LENSAR. MarketBeat recorded 5 mentions for Spectral AI and 3 mentions for LENSAR. LENSAR's average media sentiment score of 1.12 beat Spectral AI's score of 0.31 indicating that LENSAR is being referred to more favorably in the media.
LENSAR has a net margin of -34.03% compared to Spectral AI's net margin of -40.78%. Spectral AI's return on equity of 0.00% beat LENSAR's return on equity.
LENSAR and Spectral AI both received 5 outperform votes by MarketBeat users. However, 100.00% of users gave Spectral AI an outperform vote while only 38.46% of users gave LENSAR an outperform vote.
40.2% of LENSAR shares are held by institutional investors. Comparatively, 67.1% of Spectral AI shares are held by institutional investors. 38.5% of LENSAR shares are held by company insiders. Comparatively, 56.7% of Spectral AI shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Summary
Spectral AI beats LENSAR on 11 of the 18 factors compared between the two stocks.
Get Spectral AI News Delivered to You Automatically
Sign up to receive the latest news and ratings for MDAI and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Spectral AI Competitors List
Related Companies and Tools
This page (NASDAQ:MDAI) was last updated on 1/30/2025 by MarketBeat.com Staff
